Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Cannabis Use Disorder

In brief

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Key facts

Study ID

NCT07468552

Run by

National Institute on Drug Abuse (NIDA)

People needed

100

Starts

2026-11-15

Expected to finish

2028-11-15

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between 18 and 70 years of age
• Meets DSM-5 criteria for moderate or severe CUD
• Interested in treatment for cannabis use disorder
• Able to understand the study procedures and written informed consent in English
• Willing to comply with all study procedures and medication instructions
• If female, is not pregnant, and agrees to use acceptable birth control methods

You may not qualify if…

• Body Mass Index (BMI) ≤ 23 kg/m²
• Presence of a medical or psychiatric disorder that contraindicates participation in the study
• Substance use disorder other than tobacco or mild alcohol-use disorder
• Known allergy or hypersensitivity to Tirzepatide, any GLP-1 or GIP receptor agonist, or any of the excipients in the product
• Current or recent (past 30 days) use of GLP-1 receptor agonists or other weight-loss drug
• Current or recent (past 6 months) enrollment in substance use disorder treatment
• Current or planned pregnancy and breastfeeding
• Living or medical situation that would interfere with adherence to the study protocol

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.